Prostaglandin Reductase 1 as a Potential Therapeutic Target for Cancer Therapy

Frontiers in Pharmacology

Pharmacology

Longbin Zhang¹  Zufeng Guo¹  Wei Zhang¹  Kunling Song¹  Guobing Yin²  Xing Wang³ 

[1] Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing, China;Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Department of Breast and Thyroid Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing, China;

关键词: PTGR1;    tumor metabolism;    eicosanoid pathways;    cancer therapeutics;    inhibitor;   

DOI  :  10.3389/fphar.2021.717730

 received in 2021-05-31, accepted in 2021-07-29,  发布年份 2021

来源: Frontiers

【 摘 要 】

Altered tumor metabolism is a hallmark of cancer and targeting tumor metabolism has been considered as an attractive strategy for cancer therapy. Prostaglandin Reductase 1 (PTGR1) is a rate-limiting enzyme involved in the arachidonic acid metabolism pathway and mainly responsible for the deactivation of some eicosanoids, including prostaglandins and leukotriene B4. A growing evidence suggested that PTGR1 plays a significant role in cancer and has emerged as a novel target for cancer therapeutics. In this review, we summarize the progress made in recent years toward the understanding of PTGR1 function and structure, highlight the roles of PTGR1 in cancer, and describe potential inhibitors of PTGR1. Finally, we provide some thoughts on future directions that might facilitate the PTGR1 research and therapeutics development.

【 授权许可】

Unknown   
Copyright © 2021 Wang, Yin, Zhang, Song, Zhang and Guo.